Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 6
2013 8
2014 2
2015 6
2016 2
2018 3
2019 4
2020 10
2021 4
2022 5
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial.
Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider-Schur S, Starzer AM, Forstner H, Rottenmanner B, Dieckmann K, Bago-Horvath Z, Haslacher H, Widhalm G, Ilhan-Mutlu A, Minichsdorfer C, Fuereder T, Szekeres T, Oehler L, Gruenberger B, Singer CF, Weltermann A, Puhr R, Preusser M. Bartsch R, et al. Among authors: ilhan mutlu a. Nat Med. 2022 Sep;28(9):1840-1847. doi: 10.1038/s41591-022-01935-8. Epub 2022 Aug 8. Nat Med. 2022. PMID: 35941372 Free PMC article. Clinical Trial.
Circulating biomarkers of CNS tumors: an update.
Ilhan-Mutlu A, Wagner L, Preusser M. Ilhan-Mutlu A, et al. Biomark Med. 2013 Apr;7(2):267-85. doi: 10.2217/bmm.13.12. Biomark Med. 2013. PMID: 23547822 Review.
New emerging targets in cancer immunotherapy: the role of LAG3.
Puhr HC, Ilhan-Mutlu A. Puhr HC, et al. Among authors: ilhan mutlu a. ESMO Open. 2019 Mar 12;4(2):e000482. doi: 10.1136/esmoopen-2018-000482. eCollection 2019. ESMO Open. 2019. PMID: 31231559 Free PMC article. Review.
Brain metastases: pathobiology and emerging targeted therapies.
Preusser M, Capper D, Ilhan-Mutlu A, Berghoff AS, Birner P, Bartsch R, Marosi C, Zielinski C, Mehta MP, Winkler F, Wick W, von Deimling A. Preusser M, et al. Among authors: ilhan mutlu a. Acta Neuropathol. 2012 Feb;123(2):205-22. doi: 10.1007/s00401-011-0933-9. Epub 2012 Jan 3. Acta Neuropathol. 2012. PMID: 22212630 Review.
Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma-a retrospective, international, multicentric AGEO study.
Bergen ES, Pilla L, Auclin E, Ilhan-Mutlu A, Prager GW, Pietrantonio F, Antista M, Ghelardi F, Basile D, Aprile G, Longarini R, Hautefeuille V, Tougeron D, Artru P, Mabro M, Drouillard A, Roth G, Ben Abdelghani M, Clement I, Toullec C, Mineur L, Guimbaud R, Taieb J, Zaanan A. Bergen ES, et al. Among authors: ilhan mutlu a. Gastric Cancer. 2023 May;26(3):425-437. doi: 10.1007/s10120-023-01374-5. Epub 2023 Mar 7. Gastric Cancer. 2023. PMID: 36881202
46 results